3-氨甲基-5-苯基-4氢-1,2,4-三唑 | 805179-91-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 3-氨甲基-5-苯基-4氢-1,2,4-三唑
• 中文别名: (5-苯基-2H-1,2,4-噻唑-3-基)甲胺
• 英文名称: 1-(5-Phenyl-4H-1,2,4-triazol-3-yl)methanamine hydrogen chloride
• 英文别名: 1-(5-phenyl-4H-1,2,4-triazol-3-yl)methanamine；(3-Phenyl-1H-1,2,4-triazol-5-yl)methanamine
• CAS: 805179-91-3
• 化学式: C₉H₁₀N₄
• mdl: MFCD08669764
• 分子量: 174.205
• InChiKey: MMMFKWILXVDBHJ-UHFFFAOYSA-N

物化性质

• 沸点：
  397.9±44.0 °C(Predicted)
• 密度：
  1.248±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.111
• 拓扑面积：
  67.6
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-amino-2-cyclopropyl-4,6-dichloropyrimidine 、 3-氨甲基-5-苯基-4氢-1,2,4-三唑 在 N,N-二异丙基乙胺 作用下， 以 N-甲基吡咯烷酮 为溶剂， 反应 18.0h， 生成
  参考文献：
  名称：

  Discovery of triazolopyrimidine-based PDE8B inhibitors: Exceptionally ligand-efficient and lipophilic ligand-efficient compounds for the treatment of diabetes

  摘要：

  PDE8B is a cAMP-specific isoform of the broader class of phosphodiesterases (PDEs). As no selective PDE8B inhibitors had been reported, a high throughput screen was run with the goal of identifying selective tools for exploring the potential therapeutic utility of PDE8B inhibition. Of the numerous hits, one was particularly attractive since it was amenable to rapid deconstruction leading to inhibitors with very high ligand efficiency (LE) and lipophilic ligand efficiency (LLE). These triazolopyrimidines were optimized for potency, selectivity and ADME properties ultimately leading to compound 42. This compound was highly potent and selective with good bioavailability and advanced into pre-clinical development. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2012.06.079

文献信息

• [EN] NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] NOUVEAUX AGONISTES DE RÉCEPTEURS ADRÉNERGIQUES BÊTA 3 DÉRIVÉS DE PYRROLIDINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2011025774A1

  公开（公告）日：2011-03-03

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了式(I)的化合物，其药物组成物以及使用该化合物在治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。
• HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS
  申请人：Berger Richard

  公开号：US20090253705A1

  公开（公告）日：2009-10-08

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了式(I)的化合物，其药物组成物以及使用该化合物在治疗或预防由β3-肾上腺素受体激活介导的疾病的方法。
• [EN] HYDROXYMETHYL PYRROLIDINES AS BETA 3 ADRENERGIC RECEPTOR AGONISTS<br/>[FR] HYDROXYMÉTHYL PYRROLIDINES EN TANT QU'AGONISTES DE RÉCEPTEUR BÊTA 3 ADRÉNERGIQUE
  申请人：MERCK & CO INC

  公开号：WO2009124167A1

  公开（公告）日：2009-10-08

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了化合物(I)、其制药组合物以及使用它们治疗或预防由β3肾上腺素能受体激活介导的疾病的方法。
• NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS
  申请人：Edmondson Scott D.

  公开号：US20120225886A1

  公开（公告）日：2012-09-06

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了公式（I）的化合物，其药物组合物，以及使用它们治疗或预防通过激活β3肾上腺素受体介导的疾病的方法。
• Pyrrolidine derived beta 3 adrenergic receptor agonists
  申请人：Edmondson Scott D.

  公开号：US08604038B2

  公开（公告）日：2013-12-10

  The present invention provides compounds of Formula (I), pharmaceutical compositions thereof, and method of using the same in the treatment or prevention of diseases mediated by the activation of β3-adrenoceptor.

  本发明提供了I式化合物、其制药组合物以及使用该化合物治疗或预防由β3-肾上腺素能受体激活介导的疾病的方法。